Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

130.79 -0.70 (-0.53%)
Streaming Delayed Price Updated: 10:47 AM EDT, Jun 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
67 68 Next >
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
Merck's move into immunology is a risky proposition. 
Via The Motley Fool
Why BELLUS Health Stock Is Rocketing Higher Today
A $2 billion buyout agreement with GSK is lighting a fire under the biotech's stock today. 
Via The Motley Fool
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
Shares of its takeover candidate nearly doubled on the news. 
Via Investor's Business Daily
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. 
Via Benzinga
Tesla, Windtree Therapeutics, Enovix Corp, Moderna, Blackboxstocks: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
These 2 Stocks Were Monday's Big Disappointments
On a good day for the market, investors weren't happy about these decliners. 
Via The Motley Fool
S&P 500: Top 5 Performers Today Include Enphase Energy, First Solar
M&T Bank was the S&P 500's top performer. State Street was the biggest loser. 
Via Investor's Business Daily
These 3 Nasdaq Stocks Are on Fire Today: Here's Why
A high-dollar buyout is lighting a fire underneath these three Nasdaq stocks today. 
Via The Motley Fool
Wall Street Analysts Are Bullish On Moderna Stock Price: Should You?
Moderna and Merck announced positive results of its cancer vaccine. The vaccine together with Keytruda helped patients stay cancer free for 18 months. Wall Street analysts are bullish on Moderna... 
Via Talk Markets
Why Shares of Prometheus Biosciences Are Soaring Monday
Merck's $10.8 billion buyout offer sent the clinical-stage biotech stock higher. 
Via The Motley Fool
Moderna Crumbles As Cancer Vaccine Data Shows A 'Longish And Complex' Road
The path to approval isn't necessarily clear cut, according to multiple analysts. 
Via Investor's Business Daily
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations Loom
Merck is branching into immune-mediated diseases with this takeover. 
Via Investor's Business Daily
Moderna (MRNA) Stock Sinks Despite Positive Cancer Vaccine Update
MRNA stock is sinking this morning despite Moderna releasing positive Phase 2b data on its mRNA cancer vaccine yesterday. 
Via InvestorPlace
RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging Today
RXDX stock is soaring today as Merck is officially acquiring Prometheus Biosciences. Here's what investors should know today. 
Via InvestorPlace
XPeng Is Charging Higher, but This Biotech Stock Is Monday's Biggest Winner
Markets are watching corporate earnings very carefully. 
Via The Motley Fool
Why Is Prometheus Biosciences (RXDX) Stock Up 70% Today?
Prometheus Biosciences (RXDX) stock is on the rise Monday after the company revealed a $10.8 billion acquisition deal with Merck (MRK). 
Via InvestorPlace
Moderna, Merck's Cancer Vaccines Exhibit Positive Outcomes Under Midstage Trial
Via Benzinga
What's Going On With Moderna Stock Monday?
Moderna Inc (NASDAQ: MRNA) shares are trading higher Monday after the company presented data with Merck & Company Inc (NYSE: MRK) showing mRNA-4157 in combination with KEYTRUDA reduced the risk of r 
Via Benzinga
Merck Acquires Prometheus Biosciences For $10.8B, Strengthening Its Immunology Pipeline
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
Nasdaq, S&P 500 Futures Muted; Analyst Says Don't Expect Good News This Earnings Season
Early indications suggest that stocks could start the week on a tentative note, which was characteristic of trading during most of last week. Traders may show restraint as they look ahead to... 
Via Benzinga
Moderna, Merck, And A Personalized Cancer Vaccine: What Does Their AACR Presentaion Tell Us?
Moderna and Merck presented additional data on their personalize cancer vaccine. Is this a true breakthrough in cancer vaccines? 
Via Talk Markets
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Sunday, April 16
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street’s best analysts during the week of April 10-14. 
Via Talk Markets
3 Dividend Stocks to Buy for a Recession-Proof Portfolio
Many investors believe we’re at the point of no return, leading us to look at some of the best dividend stocks for a recession. 
Via InvestorPlace
10 Best Performing Blue Chip Stocks
While there may be varying interpretations among investors, the term “blue chip” typically denotes companies that are regarded as leaders in their respective fields. 
Via Talk Markets
MRK: Chart Of The Week
The 20-day moving average is coming in at about 170 – 172, which is 6 above where the current price level is. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
AMZN Stock Alert: 12 Takeaways From the 2023 Amazon Shareholder Letter
Amazon (AMZN) stock is a hot topic among traders on Thursday after CEO Andy Jassy released his annual shareholder letter. 
Via InvestorPlace
Why Is Merck (MRK) Stock Up Today?
Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda. 
Via InvestorPlace
Apple To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Thursday
Credit Suisse boosted the price target for Apple Inc. (NASDAQ: AAPL) from $184 to $188. Credit Suisse analyst Shannon Cross maintained an Outperform rating. Apple shares fell 0.4% to close at $160.10... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
67 68 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.